Company

Debiopharm

As of the edition of 20 October 2026, Debiopharm runs 15 drugs; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Active9
Went quiet2
Stopped3
Status not established1
Total15

Where it needs a new molecule

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
TargetRoute
PPIA Peptidyl-prolyl cis-trans isomerase ARoute A
BIRC2 Baculoviral IAP repeat-containing protein 2Route A
HSP90AA1 Heat shock protein HSP 90-alphaRoute A

All 3 rows on route A or B

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Infections: 14 trials led
  • Cancer: 12 trials led
  • Digestive system: 11 trials led